GlassScriptPhysician profile
Jeffrey Michael Phillips
NPI 1619130473
$3,256.26
in general payments reported to CMS, 2019-2025
29 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.41 · 2020: $153 · 2021: $420 · 2022: $186 · 2023: $873 · 2024: $1,069 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,782.42 | 2023-2025 | Inspire |
| Abbott Laboratories | $164.13 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $139.06 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $124.22 | 2021 | |
| Genzyme Corporation | $123.16 | 2020-2025 | |
| Amgen INC. | $106.71 | 2019-2024 | Prolia, Evenity |
| Radius Health, INC. | $106.27 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $75.23 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Lilly USA, LLC | $74.63 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Stryker Corporation | $46.56 | 2019-2025 | Audion Et Dilation System |
| Optinose US, INC. | $46.43 | 2020-2022 | |
| Novo Nordisk INC | $45.47 | 2023 | Rybelsus |
| Corcept Therapeutics | $44.58 | 2023-2024 | Korlym |
| Horizon Therapeutics Plc | $42.21 | 2020-2021 | |
| Insulet Corporation | $40.28 | 2021-2024 | Omnipod |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $38.57 | 2019-2021 | |
| Alk-Abello, INC | $33.49 | 2020-2021 | |
| C2dx, INC | $32.94 | 2023 | |
| Ascendis Pharma Endocrinology INC | $22.99 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $19.31 | 2022 | |
| Halozyme INC | $18.40 | 2023 | |
| Jazz Pharmaceuticals INC. | $17.95 | 2021 | |
| Eusa Pharma (US) LLC | $17.37 | 2022 | |
| Recordati_rare_diseases_inc. | $17.37 | 2022 | |
| Amryt Pharma Holdings LTD | $17.25 | 2023 | Mycapssa |
| Glaxosmithkline, LLC. | $16.92 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $15.97 | 2020 | |
| Tandem Diabetes Care, INC. | $13.22 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Olympus America INC. | $13.15 | 2024 | Rhino-Laryngo Videoscope, Gyrus Acmi, INC |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.